<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052844</url>
  </required_header>
  <id_info>
    <org_study_id>ABC-2009</org_study_id>
    <nct_id>NCT01052844</nct_id>
  </id_info>
  <brief_title>Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy</brief_title>
  <official_title>Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gabapentin is an antiepileptic drug. Its antiemetic effect is demonstrated after laparoscopic
      surgery, but it is not yet known whether gabapentin is effective in preventing chemotherapy
      induced emesis.

      The purpose of this study is to determine whether the addition of gabapentin to dexamethasone
      plus ondansetron increase the control of chemotherapy-induced nausea and vomiting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, double-blind, placebo-controlled study conducted at our institution
      (Faculdade de Medicina da Fundação ABC and affiliated Hospitals) from April 2009 to April
      2010. Patients and personnel involved in the study were blinded to the assigned treatment.
      The study was approved by the ethics committee of our institution. All the patients provided
      written informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Complete Response During Chemotherapy Course 1</measure>
    <time_frame>5 days</time_frame>
    <description>The CR was defined as no emetic episodes and no nausea episodes from day 1 to day 5 (0-120h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1</measure>
    <time_frame>6 days</time_frame>
    <description>Complete response during delayed-onset phase was defined as the absence of any episode of nausea or vomiting and no use of rescue medication when occurring during the period from days 2 through 5 after chemotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Vomiting</condition>
  <condition>Cisplatin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 300mg:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First course of chemotherapy ( cisplatin or doxorubicin at a dose of at least 50mg per
             square meter)

          -  Written informed consent must be obtained before initiating the protocol procedures

        Exclusion Criteria:

          -  ECOG 3

          -  Nausea and vomiting within the past 1 day

          -  Gastrointestinal obstruction

          -  Concurrent use of opioid

          -  Patients with brain metastases

          -  History of allergic or other adverse reaction to gabapentin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auro del Giglio, phD</last_name>
    <role>Study Director</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>September 24, 2010</results_first_submitted>
  <results_first_submitted_qc>January 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2014</results_first_posted>
  <last_update_submitted>January 18, 2014</last_update_submitted>
  <last_update_submitted_qc>January 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Felipe Melo Cruz</investigator_full_name>
    <investigator_title>MsC</investigator_title>
  </responsible_party>
  <keyword>Vomiting</keyword>
  <keyword>Antiemetics</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Antineoplastic combined chemotherapy protocols</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a prospective, double-blind, placebo-controlled study conducted at our institution (Faculdade de Medicina da Fundação ABC and affiliated Hospitals) from April 2009 to April 2010. Patients and personnel involved in the study were blinded to the assigned treatment.</recruitment_details>
      <pre_assignment_details>Patients and personnel involved in the study were blinded to the assigned treatment. The study was approved by the ethics committee of our institution. All the patients provided written informed consent. No enrolled participants were excluded from the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Placebo:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
        </group>
        <group group_id="P2">
          <title>Gabapentin</title>
          <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Gabapentin 300mg:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Placebo:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
        </group>
        <group group_id="B2">
          <title>Gabapentin</title>
          <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Gabapentin 300mg:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="10.4"/>
                    <measurement group_id="B2" value="55.6" spread="9.9"/>
                    <measurement group_id="B3" value="53.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Complete Response During Chemotherapy Course 1</title>
        <description>The CR was defined as no emetic episodes and no nausea episodes from day 1 to day 5 (0-120h)</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Placebo:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Gabapentin 300mg:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Response During Chemotherapy Course 1</title>
          <description>The CR was defined as no emetic episodes and no nausea episodes from day 1 to day 5 (0-120h)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Complete protection from nausea and vomiting (CP) was defined as the absence of any episode of nausea or vomiting and no use of rescue medication. CP was further defined as either acute (ACP), when occurring during the first 24 hours after chemotherapy; delayed (DCP), when occurring during the period from days 2 through 5 after chemotherapy; or overall, when occurring over the entire period of the study (first 120 hours).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1</title>
        <description>Complete response during delayed-onset phase was defined as the absence of any episode of nausea or vomiting and no use of rescue medication when occurring during the period from days 2 through 5 after chemotherapy</description>
        <time_frame>6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Placebo:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Gabapentin 300mg:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1</title>
          <description>Complete response during delayed-onset phase was defined as the absence of any episode of nausea or vomiting and no use of rescue medication when occurring during the period from days 2 through 5 after chemotherapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We evaluated associations between categorical variables using the Chi-Square test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were colected from day 1 to day 6 after chemotherapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Placebo:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
        </group>
        <group group_id="E2">
          <title>Gabapentin</title>
          <description>Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)
Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy
Gabapentin 300mg:
Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Felipe Melo Cruz</name_or_title>
      <organization>Faculdade de Medicina do ABC</organization>
      <phone>+55+11+27595914</phone>
      <email>felipemcruz@yahoo.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

